Medigene with strong impulseIs medigene breaking out of trendchannel or simply overbought right now. CRS and RSI strong.
Came out of a bollinger squeeze and rising.
How can you tell if its a breakout from trend? Will it continue or fall back?
−0.660EUR
−16.18 MEUR
6.03 MEUR
23.67 M
About MEDIGENE AG
Sector
Industry
CEO
Selwyn Ho
Website
Headquarters
Martinsried
Employees (FY)
86
Founded
1996
ISIN
DE000A1X3W00
FIGI
BBG000DZGHK0
MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. It focuses on the development of personalized T-cell based immunotherapies. It operates through the Immunotherapies and Other products segments. The company was founded by Ernst Ludwig Winnacker and Horst Domdey in June 1994 and is headquartered in Martinsried, Germany.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of MDG1 is 1.925 EUR — it has increased by 4.34% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on XETR exchange MEDIGENE AG stocks are traded under the ticker MDG1.
MEDIGENE AG is going to release the next earnings report on Aug 8, 2024. Keep track of upcoming events with our Earnings Calendar.
MDG1 stock is 11.54% volatile and has beta coefficient of 0.52. Check out the list of the most volatile stocks — is MEDIGENE AG there?
One year price forecast for MEDIGENE AG has a max estimate of 3.000 EUR and a min estimate of 2.350 EUR.
MDG1 earnings for the last quarter are −0.28 EUR whereas the estimation was −0.38 EUR which accounts for 26.32% surprise. Estimated earnings for the next quarter are −0.51 EUR. See more details about MEDIGENE AG earnings.
MEDIGENE AG revenue for the last quarter amounts to 3.06 M EUR despite the estimated figure of 2.50 M EUR. In the next quarter revenue is expected to reach 2.74 M EUR.
Yes, you can track MEDIGENE AG financials in yearly and quarterly reports right on TradingView.
MDG1 stock has fallen by 8.77% compared to the previous week, the month change is a 13.57% rise, over the last year MEDIGENE AG has showed a 9.69% increase.
MDG1 net income for the last quarter is −9.21 M EUR, while the quarter before that showed −6.97 M EUR of net income which accounts for −32.09% change. Track more MEDIGENE AG financial stats to get the full picture.
Today MEDIGENE AG has the market capitalization of 45.32 M, it has decreased by 2.28% over the last week.
No, MDG1 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, MDG1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MEDIGENE AG stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 86.00 employees. See our rating of the largest employees — is MEDIGENE AG on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MEDIGENE AG technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MEDIGENE AG stock shows the sell signal. See more of MEDIGENE AG technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on MEDIGENE AG future price: according to them, MDG1 price has a max estimate of 3.00 EUR and a min estimate of 2.35 EUR. Read a more detailed MEDIGENE AG forecast: see what analysts think of MEDIGENE AG and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MEDIGENE AG EBITDA is −15.03 M EUR, and current EBITDA margin is −249.04%. See more stats in MEDIGENE AG financial statements.